10659 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Condition: Recurrent Osteosarcoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
2 Not yet recruiting Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Conditions: Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions: Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
3 Not yet recruiting TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Condition: Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
4 Not yet recruiting HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
5 Recruiting Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Condition: Malignant Neoplasm
Intervention: Other: Cytology Specimen Collection Procedure
6 Not yet recruiting Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB2 Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Vaginal Cancer
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
7 Not yet recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Adult Lymphoma;   Adult Solid Neoplasm;   Advanced Malignant Neoplasm;   Refractory Malignant Neoplasm
Interventions: Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
8 Not yet recruiting Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Breast Adenocarcinoma;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
9 Not yet recruiting Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
10 Not yet recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
11 Recruiting Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Condition: Uterine Corpus Leiomyosarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
12 Not yet recruiting TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
13 Not yet recruiting Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
Conditions: Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Pomalidomide
14 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Conditions: Adult Solid Neoplasm;   Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
15 Not yet recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
16 Not yet recruiting FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer
Interventions: Procedure: Computed Tomography;   Radiation: F-18 16 Alpha-Fluoroestradiol;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
17 Not yet recruiting Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
Conditions: Adult Brain Glioblastoma;   Recurrent Adult Brain Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Temozolomide
18 Not yet recruiting FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
Condition: Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Chemotherapy;   Procedure: Computed Tomography;   Drug: Cytarabine;   Other: Fluorothymidine F-18;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
19 Not yet recruiting Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Conditions: Bile Duct Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Small Intestinal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Small Intestinal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IV Small Intestinal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ropidoxuridine
20 Not yet recruiting WEE1 Inhibitor MK-1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Belinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor MK-1775

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years